(Albany, New York) – November 04, 2026: DelveInsight’s report, “Asthma Market Insights, Epidemiology, and Market Forecast-2036,” provides a comprehensive analysis of the Asthma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
Additionally, it examines Asthma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.
Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/asthma-market
Some of the key facts of the Asthma Market Report:
The asthma market size across the 7MM was valued at approximately USD 27 billion in 2024 and is projected to grow at a CAGR of 1.9% during the 2026–2036 forecast period.
In October 2026, Clinical development in asthma continued to advance through various therapeutic approaches, particularly biologics targeting inflammatory pathways and investigational therapies for severe, uncontrolled asthma. The Phase III SOLAIRIA-1 and SOLAIRIA-2 trials evaluating GB-0895 represent ongoing efforts to explore novel treatment options for patients with severe asthma who remain inadequately controlled with existing therapies. However, the October updates reviewed did not identify any major new FDA approvals for asthma treatments or confirmed pivotal clinical trial readouts.
In Oct 2026, Omlyclo was commercially launched in the U.S., becoming the first and only FDA-approved interchangeable biosimilar to Xolair (omalizumab) for the treatment of allergic conditions and asthma, expanding patient access to an alternative treatment option.
In Sep 2026, Kelun-Biotech and its partner, Windward Bio, reported positive Phase II clinical trial results for SKB378/WIN378 in patients with asthma and announced the initiation of a Phase III study. The long-acting anti-TSLP monoclonal antibody demonstrated a significant reduction in annualized asthma exacerbation rates, along with improvements in lung function, with a twice-yearly dosing schedule. These findings highlight its potential as a convenient and competitive treatment option for patients with severe, uncontrolled asthma.
In Sep 2026, Harbour BioMed and Windward Bio announced positive Phase II results from the POLARIS trial evaluating HBM9378/WIN378 (SKB378) in patients with moderate-to-severe asthma and confirmed the initiation of a global Phase III study. The investigational ultra-long-acting, fully human monoclonal antibody targets thymic stromal lymphopoietin (TSLP) and incorporates an engineered extended half-life to enable twice-yearly subcutaneous administration. The therapy demonstrated a significant reduction in asthma exacerbations and has the potential to offer a more convenient treatment option for patients with severe inflammatory respiratory conditions.
In August 2026, Aurobindo Pharma launched a generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the U.S. through its wholly owned subsidiary, Lannett Company LLC. The product is available in 100/50 mcg and 250/50 mcg strengths and represents the first inhalation product from Aurobindo Pharma’s pipeline to reach the U.S. market. The launch highlights the company’s efforts to expand its portfolio of complex inhalation therapies. Originally developed by GSK plc, Advair Diskus is indicated as a combination therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
In July 2026, AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate) for the maintenance treatment of asthma in patients aged 12 years and older. The recommendation was supported by positive Phase III KALOS and LOGOS results, which demonstrated improvements in lung function and reductions in severe asthma exacerbations compared with dual ICS/LABA therapy. This regulatory recommendation represented an important step toward expanding access to single-inhaler triple therapy in Europe.
In March 2026, After discontinuing its branded versions of the asthma inhaler Flovent in early 2024, GSK continued supplying “authorized generics,” which are identical products marketed under different labels by partner companies. Now, genuine competition has emerged following the U.S. Food and Drug Administration approval of Glenmark Pharmaceuticals’s fluticasone propionate inhalation aerosol. This inhaled corticosteroid works by reducing lung inflammation and is indicated as a maintenance therapy for patients aged 4 years and older to help prevent symptoms such as wheezing and shortness of breath. As the first company to secure FDA approval for a generic version of Flovent, Glenmark is granted 180 days of market exclusivity before additional generic competitors can enter. The company plans to begin distribution of the product in March.
In March 2026, The U.S. Food and Drug Administration has approved the first generic version of Flovent HFA, which delivers 44 micrograms per actuation, for the maintenance treatment of asthma in patients aged 4 years and older. Flovent HFA is an inhaled corticosteroid that works by reducing lung inflammation, helping to prevent symptoms such as wheezing and shortness of breath.
In February 2026, The U.S. Food and Drug Administration has approved GSK’s Exdensur for the treatment of severe asthma in patients aged 12 years and older. The approval is based on findings from the SWIFT clinical trials, which showed a significant reduction in asthma exacerbations. As the first ultra-long-acting biologic with a six-month dosing interval, depemokimab represents a major advancement in asthma care, shifting from monthly or bi-monthly injections to a convenient twice-yearly regimen.
In December 2025, GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved Exdensur as an add-on maintenance therapy for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype. Exdensur is the first ultra-long-acting biologic being developed for respiratory diseases driven by type 2 inflammation, including severe asthma, and is engineered with an extended half-life to enable twice-yearly dosing. The approval is based on data from the Phase III SWIFT-1 and SWIFT-2 trials, where depemokimab demonstrated a sustained reduction in exacerbations with only two doses per year compared to placebo, in addition to standard care.
In September 2025, Areteia Therapeutics reported positive Phase III results from the EXHALE-4 trial, evaluating dexpramipexole as an oral add-on therapy for eosinophilic asthma, demonstrating its potential to improve outcomes in patients with this severe form of the disease.
In September 2025, The U.S. FDA approved a supplemental new drug application for Airsupra (albuterol/budesonide), updating its U.S. prescribing information to include new data for patients with mild asthma. According to AstraZeneca, this approval broadens Airsupra’s use as an anti-inflammatory rescue therapy for adults across all levels of asthma severity.
In July 2025, Asthma severity is driven by multiple inflammatory pathways, making a universal treatment approach challenging. As a result, researchers are investigating precision medicine for asthma, which focuses on identifying disease subtypes using specific biological markers (biomarkers) and customizing therapies accordingly. “Through a trial that applies precision medicine to match patients with treatments best suited to their individual profiles, we aim to replicate a strategy that has proven effective in cancer research. This platform trial design allows the simultaneous evaluation of multiple interventions in enrolled participants,” researchers explained.
In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved the primary endpoints in two Phase III asthma trials. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies showed that Breztri significantly and clinically improved lung function compared to dual-combination ICS/LABA treatments. Both randomized, double-blind trials enrolled 4,434 patients with uncontrolled asthma to assess Breztri’s efficacy as a potential therapeutic option.
In February 2025, Enveda, a biotechnology firm utilizing AI to convert natural compounds into novel therapies, has announced the expansion of its lead asset, ENV-294, into a new indication: asthma. Initially developed for atopic dermatitis, this innovative treatment presents a promising approach for managing respiratory inflammatory conditions. To advance this initiative, Enveda has formed an advisory board comprising leading experts in asthma research and clinical care.
According to DelveInsight’s estimates, the total diagnosed prevalent cases of asthma in the 7MM were around 57 million in 2024 which are expected to rise by 2036.
Among the 7MM, the US accounted for nearly 26 million of the total diagnosed prevalent cases of asthma, with around 21 million cases in adults in 2024. These cases are expected to increase during the forecast period (2026–2036).
In 2024, approximately 15.2 million females in the US were living with asthma—significantly higher than the 10.6 million cases reported among males.
Based on severity-specific asthma cases in the US, there were around 9.3 million cases of intermittent asthma, nearly 7.4 million of mild, around 7.1 million of moderate, and approximately 1.9 million of severe asthma in 2024.
In 2024, among EU4 and the UK, the UK reported the highest number of total diagnosed prevalent cases of asthma, with approximately 8.4 million cases, whereas Spain had the lowest cases, around 2.6 million.
In France, the number of adult asthma cases in 2024 nearly 3.4 million is higher than the number of pediatric cases around 1.3 million.
In Japan, as of 2024, there were an estimated 248 thousand severe asthma cases associated with Type 2 inflammation, while approximately 55 thousand cases were classified as Non-Type 2 inflammation.
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.
Asthma Overview
Asthma is a chronic inflammatory disease of the airways that makes breathing difficult. It causes the air passages in the lungs to become swollen and narrowed, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Triggers may include allergens, pollution, exercise, respiratory infections, cold air, and stress. Asthma symptoms can vary from mild to severe and may occur occasionally or persistently. Although there is no cure, asthma can be effectively managed with medications (such as inhalers), avoidance of triggers, and regular monitoring, enabling most patients to lead normal, active lives.
To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast
Asthma Epidemiology
The Asthma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Asthma Epidemiology Segmentation:
The Asthma market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Asthma
Age-specific Cases of Asthma
Gender-specific Cases of Asthma
Severity-specific Cases of Asthma
Type-specific Severity Cases of Asthma
Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast
Asthma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Asthma Therapies and Key Companies
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
TEZSPIRE (tezepelumab): Amgen/AstraZeneca
FASENRA (benralizumab): AstraZeneca
Dexpramipexole: Areteia Therapeutics
Depemokimab (GSK3511294): GlaxoSmithKline
BREZTRI AEROSPHERE (BGF; PT-010): AstraZeneca
GSK3511294 (Depemokimab): GlaxoSmithKline
Masitinib (AB07105): AB Science
PT010: AstraZeneca
Dexpramipexole Dihydrochloride: Areteia Therapeutics
ARS 1: ARS Pharmaceuticals, Inc.
MEDI3506 (tozorakimab): AstraZeneca
AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
Atuliflapon (AZD5718): AstraZeneca
Amlitelimab: Sanofi
Rilzabrutinib: Sanofi
BOXABAN (Ifetroban): Cumberland Pharmaceuticals
RG6341 (GDC-6599): Genentech Research/Roche
CBP-201: Suzhou Connect Biopharmaceuticals
AVTX-002 (Quisovalimab): Avalo Therapeutics
MRx-4DP0004: 4D Pharma plc
SB010: Sterna Biologicals
Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape
Asthma Market Drivers
Rising prevalence of asthma worldwide, especially in children and urban populations.
Increasing air pollution and environmental triggers, contributing to higher disease incidence.
Advancements in asthma therapies, including biologics, inhalers, and combination treatments.
Growing awareness and early diagnosis through improved healthcare access and education.
Supportive government initiatives and healthcare programs promoting asthma management and patient care.
Asthma Market Barriers
High cost of advanced therapies and biologics, limiting patient accessibility.
Poor patient adherence to long-term treatment regimens, reducing treatment effectiveness.
Variability in asthma severity and phenotypes, complicating personalized treatment strategies.
Limited access to healthcare in low- and middle-income regions, affecting diagnosis and management.
Potential side effects of chronic medication use, such as corticosteroids, which may deter long-term therapy.
Scope of the Asthma Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
Asthma Market Dynamics: Asthma market drivers and Asthma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement
To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Asthma Market Report Introduction
2. Executive Summary for Asthma
3. SWOT analysis of Asthma
4. Asthma Patient Share (%) Overview at a Glance
5. Asthma Market Overview at a Glance
6. Asthma Disease Background and Overview
7. Asthma Epidemiology and Patient Population
8. Country-Specific Patient Population of Asthma
9. Asthma Current Treatment and Medical Practices
10. Asthma Unmet Needs
11. Asthma Emerging Therapies
12. Asthma Market Outlook
13. Country-Wise Asthma Market Analysis (2022–2036)
14. Asthma Market Access and Reimbursement of Therapies
15. Asthma Market Drivers
16. Asthma Market Barriers
17. Asthma Appendix
18. Asthma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
